ArticleOncogene2022

Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1.

James E Melnyk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.